Oral Paclitaxel Yields Better Outcomes Than Iv Paclitaxel In Metastatic Breast Cancer

Oral paclitaxel yields better outcomes than IV paclitaxel in metastatic breast cancer

Dr. Rugo on Results of Oral Paclitaxel With Encequidar in Metastatic Breast Cancer

Oral Paclitaxel for Patients With Recurrent or Metastatic Breast Cancer

Dr. Budd Discusses Paclitaxel Regimens in Breast Cancer

The first orally administered paclitaxel shown to be superior to IV paclitaxel

Advantages of Oral Taxanes in mBC

HR+ mBC: Oral Formulations of Docetaxel and Paclitaxel

Advantages of Oral Taxanes in mBC

Disussion on the FASCINATE & PATINA Trials in Breast Cancer straight from SABCS24

Rebastinib and paclitaxel for advanced/metastatic ovarian cancer

Taxol (Paclitaxel) Chemotherapy for Breast Cancer: Side Effects, Benefits, and What to Expect

Yerbba – Breast Cancer

Advantages of Oral Taxanes in mBC

Payer Coverage of IV Versus Oral Therapy in mBC

Comment: Veliparib with carboplatin and paclitaxel in advanced gBRCA-positive breast cancers

ASCO: Newer Drugs No Better Than Paclitaxel

MDedge: news and insights for busy physicians

METEORA-II: metronomic VEX versus paclitaxel in ER+/HER2- metastatic breast cancer

Five-Year Dosing, Efficacy Results for Nab-Paclitaxel in TNBC

Targeted Oncology

Paclitaxel With Pertuzumab Plus Trastuzumab in Metastatic Breast Cancer

Advantages with Nab-Paclitaxel in TNBC

Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancer